Bibliographic details
Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab in children with congenital heart disease in Germany. Journal of Medical Economics 2009; 12(4): 301-308
MeSH
Adolescent; Antibodies, Monoclonal /administration & Antibodies, Monoclonal, Humanized; Antiviral Agents /administration & Child; Child, Preschool; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Germany; Health Services /economics /utilization; Heart Defects, Congenital /drug therapy /economics /virology; Humans; Infant; Infant, Newborn; Models, Econometric; Palivizumab; Quality-Adjusted Life Years; Respiratory Syncytial Virus Infections /drug therapy /economics /prevention & control; dosage /economics; dosage /economics